Inconsistencies in Cardiovascular Data from COX-2 Inhibitor Trials–is it a Class Effect?

Curfman G.D. , Morrissey S. , Drazen J.M. Expression of concern: Bombardier et al “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis”. N Engl J Med 2000; 343: 1520–8; 2005;353: 2813

Curfman G.D. , Morrissey S. , Drazen J.M. Expression of concern reaffirmed. [http://content.nejm.org/cgi/content/abstract/NEJMe068054]

Caldwell B. , Aldington S. , Weatherall M. , Shirtcliffe P. , Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132–40

Silverstein F.E. , Faich G. , Goldestein J.L. . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–55

White W.B. , Faich G. , Whelton A. . Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30

Witter J. Celebrex capsules (celecoxib). NDA 20-998/S-009. Medical Officer Review. US Department of Health and Human Services Food and Drug Administration, 2000 [http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf]

Jüni P. , Rutjes A.W.S. , Dieppe P.A. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287–8

Wright J.M. , Perry T.L. , Bassett K.L. , Chambers G.K. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [Letter]. JAMA 2001; 286: 2398–9

Berg Hrachovec J. , Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [Letter]. JAMA 2001; 286: 2398

Celecoxib and the CLASS trial: data massaging by industry. Prescribe Int 2002; 11: 190–1